Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Shao, Wenbo ^a   Song, Jinlong ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CHEMOEMBOLIZATION; DRUG ELUTING BEAD TRANSARTERIAL CHEMOEMBOLIZATION; HUMAN; INOPERABLE CANCER; LENGTH OF STAY; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85041723281     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010903     Document Type: Article

References (65)

1. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
2. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment for random error risk in conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38:287-98.
3. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. Journal of Vascular and Interventional Radiology 2007;18(12):1469-78. [PUBMED: 18057279]
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology 2001;35(3):421-30. [PUBMED: 11592607]
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-36. [PUBMED: 16250051]
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-2. [PUBMED: 21374666]
7. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51(4):1274-83. [PUBMED: 20112254]
8. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224(1):47-54. [PUBMED: 12091661]
9. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ (accessed 19 December 2013).
10. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127(5):1372-80. [PUBMED: 15521006]
11. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50. [PUBMED: 3616287]
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [PUBMED: 3802833]
13. Dodds HM, Walpole ET, Rivory LP, Strong RW, Pond SM. Disposition of epirubicin after intraarterial administration in lipiodol to patients with hepatocellular carcinoma. Therapeutic Drug Monitoring 1996;18(5):537-43. [PUBMED: 8885116]
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34. [PUBMED: 9310563]
15. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine 1999;340(10):745-50. [PUBMED: 10072408]
16. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatology Research 2007;37(Suppl 2):S88-S94. [PUBMED: 17877502]
17. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76. [PUBMED: 17570226]
18. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142(6):1264-73. [PUBMED: 22537432]
19. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Seminars in Liver Disease 2010;30(1):61-74. [PUBMED: 20175034]
20. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER.
21. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovascular and Interventional Radiology 2008;31(6):1141-9. [PUBMED: 18696150]
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [PUBMED: 12111919]
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557-60. [PUBMED: 12958120]
24. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
25. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clinical Cancer Research 2006;12(8):2563-7. [PUBMED: 16638866]
26. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997.
27. Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. Journal of Hepatology 1991;13(1):120-7. [PUBMED: 1655867]
28. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69(2):223-40. [PUBMED: 19228077]
29. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Alimentary Pharmacology & Therapeutics 2009;29(12):1291-8. [PUBMED: 19392861]
30. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [PUBMED: 11730399]
31. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. The Surgeon 2005;3(3):210-5. [PUBMED: 16076007]
32. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and Interventional Radiology 2010;33(1):41-52. [PUBMED: 19908093]
33. Lewandowski RJ, Geschwind J-F, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259(3):641-57.
34. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. Journal of Vascular and Interventional Radiology 2006;17(8):1335-43. [PUBMED: 16923981]
35. Lewis AL. DC Bead: a major development in the toolbox for the interventional oncologist. Expert Review of Medical Devices 2009;6(4):389-400. [PUBMED: 19572794]
36. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9. [PUBMED: 12049862]
37. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37(2):429-42. [PUBMED: 12540794]
38. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164-71. [PUBMED: 11981766]
39. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
40. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Annals of Surgical Oncology 2011;18(2):413-20. [PUBMED: 20839057]
41. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovascular and Interventional Radiology 2008;31(2):269-80. [PUBMED: 17999110]
42. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovascular and Interventional Radiology 2010;33(3):541-51. [PUBMED: 19937027]
43. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovascular and Interventional Radiology 2007;30(1):6-25. [PUBMED: 17103105]
44. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. International Journal of Cancer 2001;94(2):290-6. [PUBMED: 11668511]
45. Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, et al. Locoregional radiological treatment for hepatocellular carcinoma: which, when and how?. Cancer Treatment Reviews 2012;38(1):54-62. [PUBMED: 21726960]
46. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [PUBMED: 9746022]
47. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170(3 Pt 1):783-6. [PUBMED: 2536946]
48. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]
49. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clinical Gastroenterology and Hepatology 2007;5(9):1100-8. [PUBMED: 17627902]
50. Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70(3):585-90. [PUBMED: 1320447]
51. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
52. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
53. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
54. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
55. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [PUBMED: 7823387]
56. Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Research 2012;32(5):1769-74. [PUBMED: 22593459]
57. Thorlund K, Devereaux PJ, Wetterslev J, Gyuatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38:276-86.
58. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
59. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 19 December 2013): .
60. van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011;34(7):368-76. [PUBMED: 21734423]
61. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Journal of Hepatology 2007;46(3):474-81. [PUBMED: 17239480]
62. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al.Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR. American Journal of Roentgenology 2011;197(4):W562-W570. [PUBMED: 21940527]
63. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
64. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology 2009;9:86.
65. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.